Procalcitonin monoclonal antibody hybrid tumor 2H4 and monoclonal antibody

Abstract

The invent9ion discloses a procalcitonin monoclonal antibody hybrid tumor 2H4 and monoclonal antibody. The procalcitonin monoclonal antibody hybrid tumor 2H4 is preserved in the China Center for Type Culture Collection at 16, Dec, 2014, and the preservation number is CCTCC NO: C2014232. The monoclonal antibody prepared aiming at procalcitonin compound oligopeptide has high specificity and sensitivity to the procalcitonin protein detection and lays a foundation for the function study and development of the procalcitonin and the research of corresponding diagnostic reagents.

Description

technical field [0001] The invention relates to the field of bioengineering, in particular to a procalcitonin monoclonal antibody hybridoma 2H4 and the monoclonal antibody. Background technique [0002] Bacteria or viruses invade through wounds, respiratory tract, urinary tract, and digestive tract. In severe trauma, decreased systemic resistance, imbalance of normal flora in the body, and translocation of bacteria, it can cause severe infection symptoms in the body, which is the cause of clinical symptoms. Various complications, such as sepsis, septic shock, multiple organ dysfunction syndrome (MODS), and even the main cause of death. According to the statistics of the United States in 2001, there were 751,000 cases of severe sepsis alone in that year, and the average mortality rate was as high as 28.5%, which means that the number of deaths in that year was nearly three times that of AIDS (acquired immunodeficiency syndrome, AIDS) . Early diagnosis and timely treatment o...

AI Technical Summary

Problems solved by technology

Because in normal and healthy individuals, PCT undergoes a series of enzymatic catalysis and finally hydrolyzes to form CT, so the serum PCT concentration is extremely low, only 10-50pg / ml, which cannot be detected by general methods

Images